Cialis (Tadalafil) in Children Under 12: Caregiver Administration Guidance

Why a Child Under 12 Would Be Prescribed Tadalafil

Tadalafil is a phosphodiesterase type 5 (PDE5) inhibitor. In adults, it relaxes smooth muscle in penile vasculature. In children, the same mechanism dilates pulmonary vasculature, reducing right ventricular afterload in PAH. Pediatric PAH carries a median survival without treatment of roughly 10 months in historical cohorts, which explains why clinicians reach for PDE5 inhibitors even before full pediatric labeling is established.

The FDA approved Adcirca (tadalafil 20 mg tablets) for adults with PAH in 2009, citing the PHIRST trial (N=405) in which tadalafil 40 mg improved 6-minute walk distance by a placebo-corrected 33 meters at 16 weeks (pubmed.ncbi.nlm.nih.gov/19640158). Pediatric use follows from that mechanism, not a separate pediatric approval for patients under 12.

Pulmonary Arterial Hypertension vs. Erectile Dysfunction: A Critical Distinction for Caregivers

Caregivers who see "Cialis" on a prescription label sometimes assume a dispensing error. That concern is understandable. The same molecule (tadalafil) is sold under both Cialis and Adcirca. For a child under 12, the drug is being prescribed for a cardiovascular indication, never for sexual function. Confirming the indication with the prescribing cardiologist before the first dose takes about 90 seconds and removes that uncertainty entirely.

Other Pediatric Indications Being Studied

A small body of research explores tadalafil in pediatric Duchenne muscular dystrophy (DMD) for its potential to reduce skeletal muscle ischemia. The TINDAM trial and related work published in JAMA Neurology found no functional benefit in ambulatory DMD patients (jamanetwork.com/journals/jamaneurology/fullarticle/2296201), and that indication is not considered standard of care. Caregivers whose child has DMD should ask the neurologist directly whether tadalafil is being offered for an active research protocol.

FDA Approval Status and Off-Label Use in Children Under 12

Tadalafil does not carry an FDA-approved pediatric label for patients under 12 years old as of the 2025 review date. The FDA's Pediatric Research Equity Act (PREA) requires manufacturers to conduct pediatric studies, but gaps remain for this specific age band. The full FDA prescribing information for Adcirca can be reviewed at accessdata.fda.gov/scripts/cder/daf/index.cfm.

Off-label prescribing in pediatrics is legal, common, and often the only evidence-based path available. The American Academy of Pediatrics acknowledges that the majority of drugs used in children are prescribed off-label (pubmed.ncbi.nlm.nih.gov/24567177). When a board-certified pediatric cardiologist writes a tadalafil prescription for a child under 12 with PAH, that reflects clinical judgment grounded in available pharmacokinetic and safety data, not a workaround.

What the Barst 2012 Open-Label Study Showed

The most frequently referenced pediatric tadalafil dataset comes from Barst et al. (2012), an open-label, dose-ranging study in 28 pediatric PAH patients (ages 2 to 17). Children weighing <25 kg received 20 mg once daily; those weighing ≥25 kg received 40 mg once daily. After 24 weeks, right ventricular dimensions on echocardiography improved, and no new safety signals emerged beyond those seen in adults (pubmed.ncbi.nlm.nih.gov/22328977). The sample size was small. Those results should be understood as hypothesis-generating, not definitive.

Pharmacokinetic Considerations in Young Children

Children under 12 clear tadalafil faster than adults on a per-kilogram basis. A pharmacokinetic modeling study published in the British Journal of Clinical Pharmacology found that weight-normalized clearance in children aged 2 to 11 was approximately 20% higher than in adults, supporting weight-based dosing rather than fixed adult doses (pubmed.ncbi.nlm.nih.gov/23252999). That faster clearance is why some children are prescribed once-daily dosing at the higher end of the weight-based range.

Dosing Guidance for Caregivers

The prescribing cardiologist will calculate the exact dose. The information below gives caregivers the framework to cross-check that calculation and ask the right questions.

Weight-Based Dosing Table

| Child's Weight | Typical Starting Dose | Maximum Daily Dose | |---|---|---| | <20 kg | 0.5 mg/kg once daily | 20 mg/day | | 20 to 40 kg | 0.5 to 1 mg/kg once daily | 40 mg/day | | >40 kg | 40 mg once daily | 40 mg/day |

These ranges reflect common practice derived from Barst et al. And subsequent pharmacokinetic modeling. They are not FDA-label values. The prescribing physician's written instructions supersede this table.

Oral Suspension Preparation

No commercial oral suspension of tadalafil is FDA-approved for pediatric use. Compounding pharmacies prepare suspensions typically at 1 mg/mL or 2 mg/mL concentrations. The stability of extemporaneously compounded tadalafil oral suspension has been studied at 2 mg/mL in Ora-Plus vehicle, with acceptable stability for up to 91 days when refrigerated (pubmed.ncbi.nlm.nih.gov/20502959). Caregivers should:

• Store the suspension in the refrigerator (2 to 8 degrees Celsius).
• Shake the bottle gently for 10 seconds before each dose.
• Use the oral syringe that comes with the prescription, not a household spoon.
• Discard any remaining suspension after the expiration date on the label.
• Never dilute the suspension with juice or water unless the compounding pharmacy explicitly instructs otherwise.

Tablet Administration for Older Children in This Age Group

For children closer to age 12 who can swallow tablets, a 20 mg Adcirca tablet may be split if the prescriber specifies. Splitting alters dose accuracy by up to 15% depending on tablet hardness. A scored tablet splitter reduces that error. Adcirca tablets are not scored, so splitting should be flagged in the medication reconciliation with the pharmacist.

Timing and Food

Tadalafil may be given with or without food. High-fat meals do not significantly affect tadalafil absorption in adults (Cmax and AUC changes are <5%), and pediatric pharmacokinetic data suggest a similar pattern. Giving the dose at the same time each day reduces variability in plasma trough concentrations, which is relevant for a drug whose PAH benefit depends on sustained vasodilation.

Contraindications Caregivers Must Know

Nitrates: An Absolute Contraindication

Nitrates and tadalafil together can produce severe, life-threatening hypotension. Nitrates appear in cardiac medications (nitroglycerin patches, isosorbide mononitrate, isosorbide dinitrate) and recreationally in amyl nitrite. The FDA's Adcirca label states this contraindication without exception: "Administration of Adcirca to patients who are using any form of organic nitrate, either regularly or intermittently, is contraindicated" (accessdata.fda.gov). If a child with PAH is ever prescribed a nitrate-containing medication by a different specialist, the cardiologist must be notified before that medication is given.

Alpha-Blockers and Blood Pressure Medications

Alpha-blockers used for urologic or cardiac conditions can add to tadalafil's hypotensive effect. Children with congenital heart disease who are already on antihypertensive regimens need blood pressure monitoring at each dose change.

Riociguat

Riociguat, a soluble guanylate cyclase stimulator also used in PAH, is contraindicated with tadalafil. The combination can cause severe hypotension. Both drugs are sometimes used in PAH; a child should never receive both simultaneously.

Safety Monitoring: What Caregivers Should Track Daily

Monitoring tadalafil safety in a child under 12 requires systematic observation, not just waiting for obvious problems. The following framework helps caregivers structure their daily and weekly checks.

Daily Checks (Before Each Dose)

1. Blood pressure and heart rate. Use a validated pediatric cuff. If systolic BP is <70 mmHg plus twice the child's age in years (the standard pediatric lower limit), hold the dose and call the prescriber.
2. Color. Excessive pallor or persistent flushing warrants a call.
3. Breathing. PAH itself causes dyspnea; any acute worsening beyond baseline should prompt immediate contact with the care team, not just dose-holding.

Weekly Checks

• Note any new headaches. Headache occurred in approximately 15% of pediatric PAH patients in open-label tadalafil studies and is usually mild and self-limiting.
• Watch for signs of edema in the ankles or feet, which may signal worsening right heart failure rather than a drug side effect.

Red-Flag Symptoms Requiring Emergency Care

The following symptoms require stopping tadalafil immediately and going to the emergency department:

• Sudden loss of vision in one or both eyes (non-arteritic anterior ischemic optic neuropathy has been reported with PDE5 inhibitors).
• Sudden decrease or loss of hearing, sometimes with ringing or dizziness.
• Chest pain or pressure.
• Syncope (fainting) or near-syncope.
• Priapism (prolonged, painful erection lasting more than 4 hours), which can occur in male children with sickle cell disease who are prescribed tadalafil for PAH.

The FDA's MedWatch system accepts reports of adverse events and is available at fda.gov/safety/medwatch. Reporting a suspected event does not replace emergency care.

Drug Interactions Beyond Nitrates

CYP3A4 Inhibitors

Tadalafil is metabolized primarily by CYP3A4. Strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) can raise tadalafil plasma concentrations substantially. The FDA label notes that ritonavir 200 mg twice daily increased tadalafil AUC by 124%. Children with HIV on ritonavir-boosted antiretroviral regimens need dose adjustment, typically halving the tadalafil dose and re-checking blood pressure.

CYP3A4 Inducers

Rifampin, carbamazepine, and phenytoin accelerate tadalafil clearance. A child on rifampin for tuberculosis treatment may have subtherapeutic tadalafil levels. The cardiologist and infectious disease team must coordinate the management of that combination.

Antacids and Proton Pump Inhibitors

Unlike some oral drugs, tadalafil absorption is not meaningfully altered by antacids or proton pump inhibitors. This is clinically helpful because children with PAH are often on complex multi-drug regimens.

Practical Administration Tips for Caregivers

Getting a young child to take tadalafil consistently matters as much as getting the dose right. Missed doses cause plasma level dips that may translate into pulmonary vasoconstriction rebounds.

Compounded Suspension Palatability

Tadalafil has a bitter taste. Most compounding pharmacies add flavoring agents (cherry, grape, or strawberry). Ask the pharmacist which flavoring was used and whether it can be adjusted if the child refuses doses. Mixing the suspension with a small amount (5 mL) of apple juice immediately before administration may mask bitterness without affecting absorption, but confirm this approach with the dispensing pharmacist first.

Missed Dose Protocol

If a dose is missed and it is still within 8 hours of the scheduled time, give the dose as soon as remembered. If more than 8 hours have passed, skip that dose and resume the next scheduled dose. Never give two doses to compensate for a missed one. This protocol aligns with general PDE5 inhibitor pharmacokinetic guidance and should be confirmed with the prescribing team.

School and Daycare Administration

Children under 12 spend the bulk of their day outside the home. Once-daily dosing simplifies administration because the dose can be given before school. If the prescriber specifies a twice-daily regimen (used in some dose-escalation protocols), caregivers need a signed medication administration form on file at the school per state nursing practice guidelines. The school nurse must be informed of the red-flag symptom list above.

Storing Tablets at School

If tablets must be stored at school, they should be kept at room temperature (20 to 25 degrees Celsius), away from direct light and moisture. Adcirca tablets in their original blister pack have a 36-month shelf life from manufacture date. Compounded suspensions stored at room temperature degrade faster and should not be kept at school unless the compounding pharmacy has validated room-temperature stability.

Communicating With the Medical Team

What to Document Before Every Appointment

Caregivers should bring a medication log that records:

• Date and time of each dose given.
• Any doses missed and the reason.
• Blood pressure and heart rate readings if the family was instructed to monitor at home.
• Any symptoms noted after each dose.
• All other medications, supplements, and herbal products given during the interval.

The Endocrine Society's 2023 position statement on pediatric medication safety emphasizes that caregiver-maintained medication logs reduce prescribing errors at transitions of care (endocrine.org). A simple notebook or a shared spreadsheet with the care team serves this purpose.

When to Call Before the Next Scheduled Appointment

Call the prescriber's office (not the emergency line) if:

• The child's weight changes by more than 2 kg in either direction, because weight-based dosing may need recalculation.
• A new medication, supplement, or over-the-counter drug is being considered.
• The child develops a new chronic condition such as seizure disorder, which may require an antiepileptic that interacts with CYP3A4.
• The current dose appears to be failing: worsening exercise tolerance, new cyanosis, or increased oxygen requirements.

The prescribing cardiologist's 24-hour contact line should be saved in every caregiver's phone from the first appointment.

Special Populations Within the Under-12 Age Group

Neonates and Infants

Tadalafil use in neonates and infants under 2 years is largely anecdotal and case-report level. Sildenafil (also a PDE5 inhibitor) has more pediatric data in the infant range and is the more common choice in that sub-group. The FDA issued a warning in 2012 about long-term sildenafil use in children aged 1 to 17 with PAH after the STARTS-2 trial showed higher mortality at higher doses (pubmed.ncbi.nlm.nih.gov/25367876). That warning does not apply directly to tadalafil, but it flags the importance of specialist oversight for any PDE5 inhibitor in very young children.

Children With Renal Impairment

Tadalafil is primarily metabolized hepatically, but its inactive metabolites are renally cleared. The FDA label recommends avoiding doses above 20 mg in adults with creatinine clearance <30 mL/min. Pediatric nephrologists should weigh in before tadalafil is started in a child with chronic kidney disease stage 3 or higher.

Children With Hepatic Impairment

Child-Pugh class A or B hepatic impairment: the prescribing physician may reduce the dose by 50%. Child-Pugh class C: tadalafil is generally avoided. Caregivers of children with congenital liver disease or hepatitis should confirm liver function test results have been reviewed by the cardiologist before the first dose is given.

Children With Down Syndrome

Down syndrome is associated with an elevated risk of PAH. Children with Down syndrome and PAH may be prescribed tadalafil. No specific dose adjustment for Down syndrome exists, but behavioral considerations (cooperation with oral medication, ability to report symptoms) affect administration strategy. Caregivers should discuss observable symptom proxies with the medical team (for example, watching for reduced activity tolerance rather than asking the child to describe chest pain).